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SteroidsAbstract Aim of the work: To study the lipid profile in systemic lupus erythematosus (SLE)
patients and correlate it with disease activity parameters. The effect of hydroxychloroquine
(HCQ), steroids and azathioprine on the lipid profile was also determined.
Patients and methods: The study included 48 female SLE patients. Total cholesterol, triglycerides
and high density lipoprotein cholesterol (HDL-C) were measured in plasma. Low density lipopro-
tein cholesterol (LDL-C) and very low density lipoprotein cholesterol (VLDL) were calculated.
Disease activity was assessed using the systemic lupus activity measure (SLAM).
Results: The mean age of the patients was 25.7 ± 7 years. Hypercholesterolemia was present in
23 (47.9%) patients and hypertriglyceridemia in 16 (33.3%). There was no significant difference in
the lipid profile of SLE patients receiving 200 or 400 mg/day HCQ. No significant difference in the
lipid profile was found among patients who did not receive steroids, those who received 10 mg/day
and those who received >10 mg/day. A significant difference in cholesterol and LDL-C level was
present between SLE patients with (243.1 ± 84.3 mg/dl and 166.1 ± 65.7 mg/dl) and without
(192.7 ± 50.6 mg/dl and 115.7 ± 44.4 mg/dl) lupus nephritis (LN) (p= 0.01, p= 0.002 respec-
tively). SLAM significantly correlated with triglycerides and VLDL and negatively with HCQ
intake (r= 0.3, p= 0.04).
Conclusion: Disease activity of SLE patients affects the lipid level and its control can be helpful
in treatment strategies. The use of HCQ through its reduction of disease activity added to low dose
steroids may reduce the lipid profile of SLE patients. Control of hyerlipidemia can favourably affect
SLE renal disease.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., Postal
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The improvement in survival rates of SLE patients has led to
the recognition of premature atherosclerosis as an important
cause of coronary artery disease in these patients. One of the
important traditional factors contributing to premature
atherosclerosis is dyslipoproteinemia [1,2]. This dyslipopro-
teinemia ranges between 30% and 73% of the adult SLE
patients. Studies have shown that there are two patterns of
dyslipoproteinemia [3–5]. The first is related to active disease
where there are increased levels of triglycerides and high den-
sity lipoprotein (HDL) [6], while the second is related to high
dose steroid therapy and not related to active disease [7,8].
Actually it is difficult to differentiate between the two patterns
and there are no clear distinctive boundaries between them.
It has been shown that there is an association between ele-
vated levels of triglycerides, small dense low density
lipoprotein-cholesterol (LDL-C), low levels of HDL-C and
atherosclerosis. Steroid therapy has been shown to alter lipid
levels [9]. The administration of antimalarial drugs in SLE
patients not only treats constitutional symptoms and mild to
moderate organ involvement but it has lipid lowering proper-
ties. This is attributed to a decrease in cholesterol synthesis,
inhibition of lysosomal hydrolysis, increased uptake of LDL
and alterations in insulin resistance [10–13]. Antimalarials
are particularly effective in reducing VLDL which is the lipid
part affected by steroids. Therefore antimalarials are more effi-
cient in reducing cholesterol levels in the presence of steroids
[7].
The aim of the present study was to reveal the changes and
clinical significance of the lipid profile in SLE patients and to
correlate it with the disease activity parameters. Another aim
was to study the effect of hydroxychloroquine (HCQ), steroid
and azathioprine therapy on the lipid profile level.
2. Patients and methods
The present study included forty-eight female SLE patients
attending the Rheumatology and Rehabilitation outpatient
clinic of Cairo University Hospitals between September 2013
and July 2014. The patients fulfilled the updated American
College of Rheumatology (ACR) revised criteria for the classi-
fication of SLE [14]. The patients had a mean age of 25.7
± 7 years and a mean disease duration of 5.9 ± 4.8 years.
The patients underwent full history taking and clinical exami-
nation including cardiopulmonary, neurological, gastrointesti-
nal, renal, musculoskeletal and dermatologic examination. The
protocol of the research was approved by the institution within
which the work was undertaken and it conforms to the provi-
sions of the world association’s Declaration of Helsinki. All
patients gave informed consent. Exclusion criteria included
menopausal women and hypothyroidism. None of the patients
received lipid lowering drugs, estrogen and progesterone con-
taining agents or thyroid medication at the time of study or
three months prior to it [15]. None of the patients were smok-
ers or alcoholics.
Laboratory tests performed to the patients included com-
plete blood count, erythrocyte sedimentation rate (ESR), liver
function tests including aspartate aminotransferase (AST) and
alanine aminotransferase (ALT), kidney function tests
including blood urea nitrogen, serum creatinine and creatininePlease cite this article in press as: Ali Abdalla M et al. Clinical significance of lipid p
therapeutic potential of drugs, The Egyptian Rheumatologist (2016), http://dx.doi.oclearance as well as complete urine analysis. Antinuclear anti-
bodies (ANA) and anti-deoxyribonucleic acid antibodies (anti-
DNA) were performed by immunofluorescence and comple-
ment (C3 and C4) by radial immunodiffusion. Lipid profile
was measured after an overnight fasting. Total cholesterol
(TC) and triglycerides (TG) were measured by the calorimetric
method using commercial assays. High density lipoprotein
cholesterol (HDL-C) was measured using the direct HDL
method (Hitachi 917) [16]. Low density lipoprotein cholesterol
(LDL-C) was calculated using the formula LDL-C = TC–
(TG/2.2 + HDL-C). Very low density lipoprotein cholesterol
(VLDL) was calculated by multiplying TG by 0.45 [16].
Cholesterol levels were considered to be normal at less or equal
to 200 mg/dl, triglycerides at less or equal to 150 mg/dl, HDL-
C at more than or equal to 50 mg/dl and LDL-C at less or
equal to 130 mg/dl [17]. Disease activity was assessed using
the systemic lupus activity measure (SLAM) [18].
Chest X-ray, computed tomography of chest and echocar-
diography were performed for suspected cases of pleurisy,
interstitial pulmonary fibrosis and pancarditis. Renal biopsy
was performed for those cases of suspected lupus nephritis
based on laboratory and clinical data.
All the patients were on oral steroids except for four
patients at the time of the study, 15 patients were on a dose
of 10 mg/day and 29 patients took more than 10 mg/day.
The mean steroid dose was 15.8 ± 8.6 mg/day with a mean
duration of 3 ± 2.7 years. Twenty-one patients did not receive
antimalarials. Twenty-seven patients received hydroxychloro-
quine (HCQ) with a mean dose of 183.3 ± 179 mg/day and
a mean duration of intake of 2.7 ± 2.76 years. Ten of these
patients received a dose of 200 mg/day of HCQ with a mean
duration of intake of 3.71 ± 3.41 years and 17 patients
received 400 mg/day with a mean duration of intake of 2.18
± 2.35 years. Twenty patients received azathioprine with a
mean dose of 97.5 ± 30.24 mg/day and a mean duration of
intake of 2.79 ± 2.62 years. Five patients received pulse
cyclophosphamide monthly infusions of 0.5-1 g/m2 for
6 months for lupus nephritis and vasculitis but all had finished
the infusions at least 3 months prior to entry in the study. In
this study, 4 patients did not receive any medications, 1
received HCQ only, 11 patients took only prednisolone, 13
patients received prednisolone + HCQ, 13 patients took pred-
nisolone + HCQ+ azathioprine (AZA) and 7 patients took
prednisolone + AZA.
Statistical analysis: Data were recorded and analyzed using
the statistical package SPSS version 12. Data were expressed as
mean ± standard deviation. Comparison between 2 groups
was by Student’s t-test and more than two groups by analysis
of variance (ANOVA). Correlation was done by Pearson’s cor-
relation coefficient. P values less than 0.05 were considered sta-
tistically significant.3. Results
The study included 48 adult SLE female patients with an age
range between 17 and 45 years and a mean of 25.7 ± 7 years.
The disease duration ranged between 2 months and 18 years
with a mean of 5.9 ± 4.8 years. Systolic blood pressure ranged
between 100 and 200 mmHg with a mean of 133.5
± 25 mmHg and diastolic blood pressure ranged between 60
and 150 mmHg with a mean of 88 ± 17 mmHg. SLAM scorerofile in systemic lupus erythematosus patients: Relation to disease activity and
rg/10.1016/j.ejr.2016.08.004
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hemoglobin level was 10.4 ± 1.7 g/dl, the mean erythrocyte
sedimentation rate (ESR) in the 1st hour was 69 ± 38 mm/
hour and the mean platelet count was 318 ± 153  103/mm3.
The mean C3 was 0.74 ± 0.38 g/l and the mean C4 was 0.14
± 0.12 g/l.
Hematologic manifestations were the most prevalent occur-
ring in 33 patients (68.75%) followed by arthritis occurring in
27 patients (56.25%). Eleven patients (22.9%) had a rash
whether malar or maculopapular and 15 patients (31.25%)
had Raynaud’s phenomenon. Lupus nephritis was present in
22 patients (45.8%). Pleural effusion and pleurisy was present
in 15 patients (31.25%) and carditis in 6 (12.5%). Central ner-
vous system (CNS) manifestations were present in the form of
stroke in 3 patients (6.25%), seizures in 3 (6.25%), cranial
nerve palsy in 2 (4.2%) and psychosis in 2 (4.2%). Vasculitis
was present in 6 patients (12.5%).
The lipid profile of the SLE patients is shown in Table 1.
Hypercholesterolemia was present in 23 (47.9%) patients and
hypertriglyceridemia in 16 (33.3%).15 patients had a choles-
terol level above 240 mg/dl. Table 2 shows the lipid profile of
those patients who did not receive any antimalarials (21
patients) and those who received 200 mg/day (10 patients)
and 400 mg/day of HCQ (17 patients). There was no signifi-
cant difference between the 3 groups. A comparison was made
regarding the lipid profile of those who did not take steroids (4
patients), those who received 10 mg/day (15 patients) and
those who received more than 10 mg/day (29 patients). Also
there was no significant difference between the 3 groups
(Table 3). Table 4 makes a comparison regarding the lipid pro-
file among the patients who did not receive AZA (28 patients)
and those who received the medication (20 patients). Also the
difference was not statistically significant.
Comparison between SLE patients with (22 patients) and
without nephritis (26 patients) as regards the lipid profile
showed only significant differences in the cholesterol level
and the LDL-C level (Table 5). While comparison of the lipid
profile between the SLE patients with CNS (10 patients) and
without CNS manifestations (38 patients) did not show any
statistically significant differences (Table 6).
Correlation of the various lipid profile parameters was done
with a few disease activity parameters. Triglycerides and
VLDL cholesterol showed a significant correlation with the
SLAM index (p= 0.04 for both). There was no significant cor-
relation between the lipid profile subfractions and ESR, C3,
C4 or platelet count (Table 7). There was a significant negativeTable 1 The lipid profile of the SLE patients.
Lipid profile
Mean ± SD (range)
SLE patients (n= 48)
TC (mg/dl) 212.2 ± 73.9 (69–447)
HDL-C (mg/dl) 40.02 ± 11.2 (17–98)
LDL-C (mg/dl) 137.6 ± 59.6 (43.2–321.4)
TG (mg/dl) 169.6 ± 79.9 (56–383)
VLDL (mg/dl) 80.3 ± 42.3 (25.2–242.1)
TC: total cholesterol; HDL-C: high density lipoprotein-cholesterol;
LDL-C: low density lipoprotein-cholesterol; TG: triglycerides;
VLDL: very low density lipoprotein-cholesterol.
Please cite this article in press as: Ali Abdalla M et al. Clinical significance of lipid p
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p= 0.04) (not shown in the tables).
4. Discussion
Reports in the literature of premature atherosclerosis in SLE
patients have been attributed to traditional risk factors as well
as to the disease process itself and to its treatment [19,20]. One
of these traditional risk factors is dyslipidemia which is a com-
mon finding in SLE [21].
In the present study we reported hypercholesterolemia
(>200 mg/dl) in 23 patients (47.9%), 15 of these patients
had a cholesterol level >240 mg/dl. Hypercholestrolemia’s
prevalence varies between the different studies. Manzi and
his colleagues reported a 5.4% prevalence as he chose
>240 mg/dl as his upper limit [1]. While Bruce et al. reported
a prevalence of 33.6% and this difference between our study
and his is most probably related to ethnic variations and life-
style factors [22]. The result was in accordance to that of a
study on 221 Egyptian SLE patients showing hypercholes-
terolemia in 51.1% [23].
The present study shows that the cholesterol, LDL-C,
HDL-C, triglycerides and the VLDL cholesterol levels were
reduced in patients receiving HCQ compared to those not
receiving the drug. The values were not statistically significant
and the 400 mg/day dose was not more efficient in lowering the
lipid profile than the 200 mg/day dose. In agreement with our
results were those of Rossoni et al. [24] and Tam et al. [25] who
showed that the lipid profile did not differ among users and
non-users of chloroquine. Other authors have reported the
beneficial decrease of cholesterol, triglycerides, LDL-C and
VLDL cholesterol levels after antimalarial treatment whether
chloroquine or HCQ [6,15,26,27]. These differences in our
results and other authors can be attributed to our small num-
ber of patients and to other factors such as the disease dura-
tion, duration of intake of antimalarials and the concomitant
use of other medications.
Our results showed that all the lipid profile values were
higher in the patients taking more than 10 mg prednisone/day
than those receiving 10 mg/day but these values were not
higher than those not receiving any prednisone. We were con-
sistent with the results of Sarkissian et al. [28] regarding the
cholesterol and the LDL-C levels but we were different regard-
ing the HDL-C levels which they demonstrated were higher in
patients receiving prednisone compared to those not receiving
the drug. This discrepancy can be due to the fact that
decreased HDL-C is associated with active disease and those
receiving high dose prednisone were those with active disease.
Svenungsson et al. [6] have also commented on this association
between low HDL-C levels and active SLE. Our results are
also in accordance with Petri and his colleagues who showed
that low daily prednisone doses do not significantly affect
the lipid profile. In fact they showed that for each 10 mg
increase in prednisone dose there was a 7.5 ± 1.46 mg%
increase in cholesterol level [7].
In this study there was no difference in the lipid profile
between those patients who received AZA and those who did
not receive the drug. This is consistent with the results of
Rho and his colleagues who showed no difference in the lipid
profile among SLE patients who received the drug versus thoserofile in systemic lupus erythematosus patients: Relation to disease activity and
rg/10.1016/j.ejr.2016.08.004
Table 2 The lipid profile of the SLE patients according to hydroxychloroquine intake.
Lipid profile
Mean ± SD
SLE patients according to HCQ intake and dose (n= 48)
No HCQ
(n= 21)
200 mg/day
(n= 10)
400 mg/day
(n= 17)
P
TC (mg/dl) 227.1±82.5 206.1 ± 77.6 206.5 ± 54.5 0.63
HDL-C (mg/dl) 41.8±16.4 39.3 ± 7.96 38.6 ± 3.8 0.69
LDL-C (mg/dl) 125.7±53.5 133.5 ± 68.7 136.4 ± 49.9 0.84
TG (mg/dl) 184.4±91.4 166.4 ± 79.5 157.7 ± 65.6 0.6
VLDL (mg/dl) 91.2±53.5 74.99 ± 35.9 70.9 ± 29.5 0.33
TC: total cholesterol; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein-cholesterol; TG: triglycerides; VLDL: very
low density lipoprotein-cholesterol; HCQ: hydroxychloroquine.
Table 3 The lipid profile of the SLE patients according to oral prednisone intake.
Lipid profile
Mean ± SD
SLE patients according to prednisone intake and dose (n= 48)
No use
(n = 4)
10 mg/day
(n= 15)
>10 mg/day
(n= 29)
P
TC (mg/dl) 240.3 ± 48.4 187.7 ± 65.6 220.9 ± 79.1 0.23
HDL-C (mg/dl) 54.3 ± 29.4 37.6 ± 7.4 39.3 ± 7.4 0.32
LDL-C (mg/dl) 137.8 ± 73.2 125.2 ± 51.4 143.8 ± 62.7 0.67
TG (mg/dl) 243.0 ± 57.9 167.8 ± 58 175 ± 110 0.13
VLDL (mg/dl) 109.4 ± 26.0 75.5 ± 26.1 78.8 ± 49.5 0.13
TC: Total Cholesterol; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein-cholesterol; TG: triglycerides; VLDL:
very low density lipoprotein-cholesterol.
Table 4 The lipid profile of the SLE patients according to
azathioprine intake.
Lipid profile
Mean ± SD
SLE patients according to azathioprine intake
(n= 48)
No use
(n= 28)
With AZA intake
(n= 20)
P
TC (mg/dl) 214.2 ± 65.5 215.4 ± 78.3 0.48
HDL-C (mg/dl) 40.2 ± 13.4 40.7 ± 6.8 0.45
LDL-C (mg/dl) 130.7 ± 54 142.2 ± 66.4 0.26
TG (mg/dl) 194.6 ± 99.6 162.7 ± 87.3 0.87
VLDL (mg/dl) 87.6 ± 44.8 75.5 ± 26.1 0.87
AZA: azathioprine; TC: total cholesterol; HDL-C: high density
lipoprotein-cholesterol; LDL-C: low density lipoprotein-choles-
terol; TG: triglycerides; VLDL: very low density lipoprotein-
cholesterol.
Table 5 The lipid profile of the SLE patients with and without
nephritis.
Lipid profile
Mean ± SD
SLE patients (n= 48)
Without LN
(n= 26)
With LN
(n= 22)
P
TC (mg/dl) 192.7 ± 50.6 243.1 ± 84.3 0.01*
HDL-C (mg/dl) 40.2 ± 13.8 39.9 ± 7.0 0.54
LDL-C (mg/dl) 115.7 ± 44.4 166.1 ± 65.7 0.002*
TG (mg/dl) 183.8 ± 76.6 153.5 ± 81.4 0.9
VLDL (mg/dl) 82.7 ± 34.5 73.2 ± 39.3 0.9
TC: total cholesterol; HDL-C: high density lipoprotein-cholesterol;
LDL-C: low density lipoprotein cholesterol; TG: triglycerides;
VLDL: very low density lipoprotein cholesterol.
* p< 0.05.
4 M. Ali Abdalla et al.who did not [29]. As AZA is given concomitantly with steroids
with or without HCQ as a steroid sparing agent and in the
induction of remission of lupus cases, it is difficult to interpret
its effect on lipids. Therefore further studies with follow up of
the patients are needed to determine its lipid effect.
The lipid profile of our lupus patients showed that there
were significantly higher cholesterol and LDL-C levels in
patients with lupus nephritis compared to those without. This
is in agreement with several authors who reported that dyslipi-
demia can hasten renal damage through hyperfiltration injury,
glomerulosclerosis and tubulointerstitial injury [30–32]. Tissev-
erasinghe et al. revealed that hypercholesterolemia was an
independent factor that predicted unfavourable renal outcome
and mortality [33].Please cite this article in press as: Ali Abdalla M et al. Clinical significance of lipid p
therapeutic potential of drugs, The Egyptian Rheumatologist (2016), http://dx.doi.oThe present study revealed that although SLE patients with
CNS manifestations (10 patients) had higher mean cholesterol
and LDL-C levels compared to SLE patients without CNS
manifestations but the differences were not statistically signif-
icant. This is contrary to a study performed by Mikdashi et al.
who showed that hypercholestrolemia was more common in
SLE patients with ischemic stroke [17]. Probably the difference
between our results and this study is due to our small number
of patients and that the study had an 8 year follow up of
patients which we did not perform.
We found in this study that triglycerides and VLDL choles-
terol significantly correlated with SLAM index. Sarkissian
et al. revealed similar results showing that triglyceride levels
tended to decrease with the corresponding reduction in diseaserofile in systemic lupus erythematosus patients: Relation to disease activity and
rg/10.1016/j.ejr.2016.08.004
Table 6 The lipid profile of the SLE patients with and without CNS manifestations.
Lipid profile
Mean ± SD
SLE patients (n= 48)
Without CNS
(n= 38)
With CNS
(n= 10)
P
TC (mg/dl) 212.3 ± 74.4 216.6 ± 61.8 0.43
HDL-C (mg/dl) 40.7 ± 11.8 37.9 ± 9.4 0.78
LDL-C (mg/dl) 131.7 ± 61.7 146.5 ± 48.9 0.22
TG (mg/dl) 171.8 ± 77.0 161.9 ± 94.4 0.62
VLDL (mg/dl) 77.9 ± 34.2 72.9 ± 42.5 0.63
TC: total cholesterol; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein-cholesterol; TG: triglycerides; VLDL: very
low density lipoprotein-cholesterol.
Table 7 Correlation between lipid profile and disease activity variables in SLE patients.
Lipid profile
r (p)
Disease activity variables in SLE patients (n= 48)
SLAM ESR C3 C4 Pl count
TC 0.03 (0.84) 0.05 (0.73) 0.08 (0.61) 0.03 (0.84) 0.11 (0.46)
HDL-C 0.08 (0.61) 0.06 (0.67) 0.1 (0.49) 0.04 (0.81) 0.05 (0.73)
LDL-C 0.1 (0.49) 0.12 (0.42) 0.12 (0.42) 0.06 (0.67) 0.05 (0.73)
TG 0.3* (0.04) 0.24 (0.1) 0.14 (0.34) 0.09 (0.53) 0.002 (0.99)
VLDL 0.3* (0.04) 0.24 (0.1) 0.14 (0.34) 0.09 (0.53) 0.002 (0.99)
TC: total cholesterol; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein-cholesterol; TG: triglycerides; VLDL: very
low density lipoprotein-cholesterol; SLAM: systemic lupus activity measure; ESR: erythrocyte sedimentation rate; C3 and C4: Complement
factor 3 and 4; Pl: platelet.
* p< 0.05.
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activity index (SLEDAI) [28]. Several authors also docu-
mented the increase of triglycerides and VLDL cholesterol
with active SLE and that both lipid subfractions denote con-
tinuous inflammatory process and the effect of prednisone
treatment [34,35].
Although in the present study there was not a statistically
significant difference between SLE patients receiving HCQ
treatment and those that did not but there was a significant
negative correlation between HCQ treatment and the SLAM
index. This can have therapeutic implications as it denotes that
administration of HCQ can affect SLE disease activity and
consequently the lipid profile of the patients. Also, if this treat-
ment is administered with low dose steroids it can have a ben-
eficial lipid lowering effect.
It is very hard to interpret lipid profile results as there are
multiple confounding factors such as lifestyle factors, medica-
tions and comorbidities that can develop during the course of
the disease. We can draw broad observations from this study
as the number of patients was small to give conclusive evi-
dence. We deduce that HCQ through its effect on disease activ-
ity of SLE patients when administered with low dose steroids
may reduce even to a small extent cholesterol, triglyceride,
LDL-C and VLDL levels. Proper treatment of hypercholes-
terolemia should be tackled promptly to avoid the poor renal
outcome which it imposes on SLE patients.Conflict of interest
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